Increased proportion of the CD56bright NK cell subset in patients chronically infected with Hepatitis C Virus (HCV) receiving interferon-α and ribavirin therapy

Journal of Medical Virology

Volumn 82, Issue 4, 2010, Pages 568-574

  Lee, Silvia ^a,b   Watson, Mark W ^a   Flexman, James P ^a   Cheng, Wendy ^a   Hammond, Talia ^b   Price, Patricia ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Flow cytometry; HCV; Natural killer cells; Therapy

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; PEGATRON; PEGINTERFERON ALPHA2A; PERFORIN; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER INJURY; MALE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; VIRUS DETECTION;

ADULT; AGED; ANTIGENS, CD3; ANTIGENS, CD56; ANTIVIRAL AGENTS; FEMALE; FLOW CYTOMETRY; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; RIBAVIRIN; YOUNG ADULT;

HEPATITIS C VIRUS;

EID: 77949381825     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21742     Document Type: Article

References (25)

1. Baroni GS, D'Ambrosio L, Curto P, Casini A, Mancini R, Jezequel AM, Benedetti A. 1996. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 23:1189-1199.
2. Bedossa P, Poynard T. 1996. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24:289-293.
3. Bonorino P, Ramzan M, Camous X, Dufeu-Duchesne T, Thélu MA, Sturm N, Dariz A, Guillermet C, Pernollet M, Zarski JP, Marche PN, Leroy V, Jouvin-Marche E. 2009. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. J Hepatol 51:458-467.
4. Bullock GC, Bruns DE, Haverstick DM. 2002. Hepatitis C genotype determination by melting curve analysis with a single set of fluorescence resonance energy transfer probes. Clin Chem 48:2147-2154.
5. Castelain S, Descamps V, Thibault V, François C, Bonte D, Morel V, Izopet J, Capron D, Zawadzki P, Duverlie G. 2004. TaqMan amplification system with an internal positive controls for HCV RNA quantitation. J Clin Virol 31:227-234.
6. Cooper MA, Fehniger TA, Caligiuri MA. 2001. The biology of human natural killer-cell subsets. Trends Immunol 22:633-640.
7. Corado J, Toro F, Rivera H, Bianco NE, Deibis L, De Sanctis JB. 1997. Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. Clin Exp Immunol 109:451-457.
8. Deutsch M, Hadziyannis SJ. 2008. Old and emerging therapies in chronic hepatitis C: An update. J Viral Hepat 15:2-11.
9. Düesberg U, Schneiders AM, Flieger D, Inchauspé G, Sauerbruch T, Spengler U. 2001. Natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) is not impaired in patients suffering from chronic hepatitis C. J Hepatol 35:650-657.
10. Feld JJ, Hoofnagle JH. 2005. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436:967-972.
11. Golden-Mason L, Madrigal-Estebas L, McGrath E, Conroy MJ, Ryan EJ, Hegarty JE, O'Farrelly C, Doherty DG. 2008. Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure. Gut 57:1121-1128.
12. Gonzalez VD, Falconer K, Michaëlsson J, Moll M, Reichard O, Alaeus A, Sandberg JK. 2008. Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: Reversion by antiviral treatment with pegylated IFNalpha and ribavirin. Clin Immunol 128:46-56.
13. Itose I, Kanto T, Inoue M, Miyazaki M, Miyatake H, Sakakibara M, Yakushijin T, Oze T, Hiramatsu N, Takehara T, Kasahara A, Katayama K, Kato M, Hayashi N. 2007. Involvement of dendritic cell frequency and function in virological relapse in pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C patients. J Med Virol 79:511-521.
14. Kawarabayashi N, Seki S, Hatsuse K, Ohkawa T, Koike Y, Aihara T, Habu Y, Nakagawa R, Ami K, Hiraide H, Mochizuki H. 2000. Decrease of CD56(+)T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology 32:962-969.
15. Lin AW, Gonzalez SA, Cunningham-Rundles S, Dorante G, Marshall S, Tignor A, Ha C, Jacobson IM, Talal AH. 2004. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection. Clin Exp Immunol 137:408-416.
16. Meier UC, Owen RE, Taylor E, Worth A, Naoumov N, Willberg C, Tang K, Newton P, Pellegrino P, Williams I, Klenerman P, Borrow P. 2005. Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J Virol 79:12365-12374.
17. Melhem A, Muhanna N, Bishara A, Alvarez CE, Ilan Y, Bishara T, Horani A, Nassar M, Friedman SL, Safadi R. 2006. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 45:60-71.
18. Morishima C, Paschal DM, Wang CC, Yoshihara CS, Wood BL, Yeo AE, Emerson SS, Shuhart MC, Gretch DR. 2006. Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing. Hepatology 43:573-580.
19. Pár G, Rukavina D, Podack ER, Horányi M, Szekeres-Barthó J, Hegedüs G, Paál M, Szereday L, Mózsik G, Pár A. 2002. Decrease in CD3-negative-CD8dim(+) and Vdelta2/Vgamma9 TcR+ peripheral blood lymphocyte counts, low perforin expression and the impairment of natural killer cell activity is associated with chronic hepatitis C virus infection. J Hepatol 37:514-522.
20. Pernollet M, Jouvin-Marche E, Leroy V, Vigan I, Zarski JP, Marche PN. 2002. Simultaneous evaluation of lymphocyte subpopulations in the liver and in peripheral blood mononuclear cells of HCV-infected patients: Relationship with histological lesions. Clin Exp Immunol 130:518-525.
21. Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. 2009. CD56bright natural killer (NK) cells: An important NK cell subset. Immunology 126:458-465.
22. Vitale M, Della Chiesa M, Carlomagno S, Romagnani C, Thiel A, Moretta L, Moretta A. 2004. The small subset of CD56brightCD16-natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells. Eur J Immunol 34:1715-1722.
23. Watson MW, Jaksic A, Price P, Cheng W, McInerney M, French MA, Fisher S, Lee S, Flexman JP. 2003. Interferon-gamma response by peripheral blood mononuclear cells to hepatitis C virus core antigen is reduced in patients with liver fibrosis. J Infect Dis 188:1533-1536.
24. Yamagiwa S, Matsuda Y, IchidaT, Honda Y, Takamura M, Sugahara S, Ishikawa T, Ohkoshi S, Sato Y, Aoyagi Y. 2008. Sustained response to interferon-alpha plus ribavirin therapy for chronic hepatitis C is closely associated with increased dynamism of intrahepatic natural killer and natural killer T cells. Hepatol Res 38:664-672.
25. Zarife MA, Reis EA, Carmo TM, Lopes GB, Brandão EC, Silva HR, Santana N, Martins-Filho OA, Reis MG. 2009. Increased frequency of CD56Bright NK-cells, CD3-CD16+CD56- NK-cells and activated CD4+T-cells or B-cells in parallel with CD4+CD25High T-cells control potentially viremia in blood donors with HCV. J Med Virol 81:49-59.